Gamma Biotherapeutics is a private clinical stage biotech company developing a novel fas ligand inhibitor (M3T01) for the treatment of advanced cancers. M3T01 is a fully human IgG4/kappa monoclonal antibody that is being evaluated in a first-in-human phase I clinical trial as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (NCT06719362).